# New Insights on Cannabis-Based Medicines for Insomnia > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-based-medicines-insomnia-treatment-insights/ > **Published:** 2026-03-19T22:54:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:04:47-04:00 > **Clinical Summary:** Explore cannabis-based medicines insomnia treatment and their potential as alternatives for patients with refractory insomnia. --- A recent study published in PLOS Mental Health has provided new insights into the therapeutic potential of cannabis-based medicines for insomnia treatment. With approximately 10% of the global adult population affected by insomnia, researchers investigated whether prescribed cannabis-based medicinal products could offer an [alternative treatment](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) option for patients who have not responded to conventional therapies. Table of Contents - [Study Design and Patient Population](#Study_Design_and_Patient_Population) - [Treatment Protocols and Dosing Patterns](#Treatment_Protocols_and_Dosing_Patterns) - [Clinical Implications and Current Treatment Landscape](#Clinical_Implications_and_Current_Treatment_Landscape) - [Clinical Takeaways](#Clinical_Takeaways)[Related](#Related) ## Study Design and Patient Population The research, titled “UK [Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) Registry: A clinical outcomes analysis for insomnia,” analyzed data from 124 adult patients enrolled in the UK [Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) Registry (UKMCR). All participants had confirmed insomnia diagnoses and had previously failed to improve with at least two licensed medications before being prescribed [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). The study employed a longitudinal approach, tracking patient-reported outcome measures (PROMs) and adverse events over an 18-month period, with assessments conducted at 1, 3, 6, 12, and 18 months post-treatment initiation. This comprehensive follow-up period allowed researchers to evaluate both short-term and longer-term effects of cannabis-based interventions. ## Treatment Protocols and Dosing Patterns The prescribed cannabis-based medicines contained varying ratios of cannabidiol (CBD) and tetrahydrocannabinol (THC). Dosing patterns showed significant variation over the treatment period: - **CBD dosing:** Median daily doses increased from 1 mg at baseline to 10 mg by month 3, remaining stable through month 18 - **THC dosing:** More substantial increases were observed, with median daily doses rising from 20 mg at baseline to 120 mg by month 18 These dosing patterns suggest that patients may require individualized titration protocols, with THC doses showing greater variability in optimal therapeutic ranges compared to CBD. ## Clinical Implications and Current Treatment Landscape Current standard treatments for insomnia include cognitive behavioral therapy for insomnia (CBT-I) and prescription medications. However, these approaches face significant limitations, including provider shortages for CBT-I and limited evidence regarding long-term effects of pharmacological interventions. The growing interest in [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) reflects the need for additional therapeutic options, particularly for treatment-resistant cases. The study contributes to an emerging body of research examining cannabinoid medicinal products for sleep disorders, though the authors acknowledge that evidence regarding efficacy remains limited and requires further investigation. ## Clinical Takeaways This registry-based study represents an important step in understanding the real-world application of cannabis-based medicines for insomnia treatment. The research design allows for observation of treatment patterns in clinical practice settings, providing valuable insights into dosing strategies and patient response over extended periods. However, healthcare providers should note that this represents observational data rather than controlled clinical trial evidence. The findings suggest that cannabis-based medicines may offer a viable treatment option for patients with refractory insomnia, particularly those who have not responded to conventional therapies. The observed dosing patterns indicate the importance of individualized treatment approaches and careful monitoring during titration phases. As research in this field continues to evolve, these registry-based studies provide crucial real-world evidence to inform clinical decision-making and guide future controlled trials in cannabis-based sleep medicine. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Medical cannabis patients report improved sleep quality, according to newly published …](https://cedclinic.com/medical-cannabis-sleep-quality-study-patient-benefits/) Discover patient-reported improvements in sleep quality linked to medical [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in this recent study. [Read More](https://cedclinic.com/medical-cannabis-sleep-quality-study-patient-benefits/) [Cannabinoids Show Short-Term Promise for Sleep Apnea, But Evidence Remains Too Thin for Clinical Use](https://cedclinic.com/cannabinoids-sleep-apnea-systematic-review/) A systematic review exploring cannabinoids’ potential in sleep apnea treatment and current evidence limitations. [Explore Findings](https://cedclinic.com/cannabinoids-sleep-apnea-systematic-review/) [Cannabinoid Clinical Trials: Mental Health Evidence Review](https://cedclinic.com/cannabinoid-clinical-trials-mental-health-evidence-review/) Review clinical trial data on cannabinoids and their impact on mental health, relevant to sleep and [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/). [Learn More](https://cedclinic.com/cannabinoid-clinical-trials-mental-health-evidence-review/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=New%20Insights%20on%20Cannabis-Based%20Medicines%20for%20Insomnia&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-based-medicines-insomnia-treatment-insights%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-based-medicines-insomnia-treatment-insights%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=New%20Insights%20on%20Cannabis-Based%20Medicines%20for%20Insomnia%20https%3A%2F%2Fcedclinic.com%2Fcannabis-based-medicines-insomnia-treatment-insights%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).